{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:25:54Z","timestamp":1791872754505,"version":"4.3.4"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100021821","name":"Oncode Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021821","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004622","name":"The Dutch Cancer Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO J"],"published-print":{"date-parts":[[2023,3,1]]},"DOI":"10.15252\/embj.2022111614","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T08:20:58Z","timestamp":1675066858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["TSC2 regulates tumor susceptibility to TRAIL\u2010mediated T\u2010cell killing by orchestrating mTOR signaling"],"prefix":"10.1038","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5874-8001","authenticated-orcid":false,"given":"Chun\u2010Pu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joleen J H","family":"Traets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6718-1422","authenticated-orcid":false,"given":"David W","family":"Vredevoogd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils L","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1293-3177","authenticated-orcid":false,"given":"Daniel S","family":"Peeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"BFEMBJ2022111614_CR1","volume":"1865","author":"K Abe","year":"2019","unstructured":"Abe K, Yano T, Tanno M, Miki T, Kuno A, Sato T, Kouzu H, Nakata K, Ohwada W, Kimura Y et\u00a0al (2019) mTORC1 inhibition attenuates necroptosis through RIP1 inhibition\u2010mediated TFEB activation. Biochim Biophys Acta Mol Basis Dis 1865: 165552","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"BFEMBJ2022111614_CR2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/01.ju.0000074621.74361.10","volume":"170","author":"H Adachi","year":"2003","unstructured":"Adachi H, Igawa M, Shiina H, Urakami S, Shigeno K, Hino O (2003) Human bladder tumors with 2\u2010hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. J Urol 170: 601\u2013604","journal-title":"J Urol"},{"key":"BFEMBJ2022111614_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29442-x","author":"G Apriamashvili","year":"2022","unstructured":"Apriamashvili G, Vredevoogd DW, Krijgsman O, Bleijerveld OB, Ligtenberg MA, de Bruijn B, Boshuizen J, Traets JJH, D\u2019Empaire Altimari D, van Vliet A et\u00a0al (2022) Ubiquitin ligase STUB1 destabilizes IFN\u03b3-receptor complex to suppress tumor IFN\u03b3 signaling. Nat Commun 13. https:\/\/doi.org\/10.1038\/s41467-022-29442-x","journal-title":"Nat Commun"},{"key":"BFEMBJ2022111614_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scisignal.2005326","volume":"7","author":"J Aramburu","year":"2014","unstructured":"Aramburu J, Ortells MC, Tejedor S, Buxad\u00e9 M, L\u00f3pez\u2010Rodr\u00edguez C (2014) Transcriptional regulation of the stress response by mTOR. Sci Signal 7: 1\u201312","journal-title":"Sci Signal"},{"key":"BFEMBJ2022111614_CR5","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1038\/sj.onc.1204009","volume":"19","author":"G Benvenuto","year":"2000","unstructured":"Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle JP, Halley DJJ, Sampson JR, Wienecke R, DeClue JE (2000) The tuberous sclerosis\u20101 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 19: 6306\u20136316","journal-title":"Oncogene"},{"key":"BFEMBJ2022111614_CR6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.molcel.2008.02.024","volume":"30","author":"L Bozulic","year":"2008","unstructured":"Bozulic L, Surucu B, Hynx D, Hemmings BA (2008) PKBalpha\/Akt1 acts downstream of DNA\u2010PK in the DNA double\u2010strand break response and promotes survival. Mol Cell 30: 203\u2013213","journal-title":"Mol Cell"},{"key":"BFEMBJ2022111614_CR7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1083\/jcb.200507119","volume":"173","author":"SL Cai","year":"2006","unstructured":"Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiguchi K, Walker CL (2006) Activity of TSC2 is inhibited by AKT\u2010mediated phosphorylation and membrane partitioning. J Cell Biol 173: 279\u2013289","journal-title":"J Cell Biol"},{"key":"BFEMBJ2022111614_CR8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI84262","volume":"127","author":"J Cao","year":"2017","unstructured":"Cao J, Tyburczy ME, Moss J, Darling TN, Widlund HR, Kwiatkowski DJ (2017) Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation. J Clin Invest 127: 349\u2013364","journal-title":"J Clin Invest"},{"key":"BFEMBJ2022111614_CR9","doi-asserted-by":"crossref","first-page":"32493","DOI":"10.1074\/jbc.C300226200","volume":"278","author":"AF Castro","year":"2003","unstructured":"Castro AF, Rebhun JF, Clark GJ, Quilliam LA (2003) Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin\u2010 and farnesylation\u2010dependent manner. J Biol Chem 278: 32493\u201332496","journal-title":"J Biol Chem"},{"key":"BFEMBJ2022111614_CR10","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1038\/sj.onc.1204736","volume":"20","author":"X Chen","year":"2001","unstructured":"Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK (2001) Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073\u20136083","journal-title":"Oncogene"},{"key":"BFEMBJ2022111614_CR11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","volume":"125","author":"H Chi","year":"2012","unstructured":"Chi H (2012) Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol 125: 325\u2013338","journal-title":"Nat Rev Immunol"},{"key":"BFEMBJ2022111614_CR12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.tips.2014.11.004","volume":"36","author":"F Chiarini","year":"2015","unstructured":"Chiarini F, Evangelisti C, McCubrey JA, Martelli AM (2015) Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci 36: 124\u2013135","journal-title":"Trends Pharmacol Sci"},{"key":"BFEMBJ2022111614_CR13","doi-asserted-by":"crossref","first-page":"8313","DOI":"10.1074\/jbc.C500451200","volume":"281","author":"H Chong\u2010Kopera","year":"2006","unstructured":"Chong\u2010Kopera H, Inoki K, Li Y, Zhu T, Garcia\u2010Gonzalo FR, Rosa JL, Guan KL (2006) TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J Biol Chem 281: 8313\u20138316","journal-title":"J Biol Chem"},{"key":"BFEMBJ2022111614_CR14","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.4049\/jimmunol.176.5.2730","volume":"176","author":"S Colombetti","year":"2006","unstructured":"Colombetti S, Basso V, Mueller DL, Mondino A (2006) Prolonged TCR\/CD28 engagement drives IL\u20102\u2010independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J Immunol 176: 2730\u20132738","journal-title":"J Immunol"},{"key":"BFEMBJ2022111614_CR15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.immuni.2009.04.014","volume":"30","author":"GM Delgoffe","year":"2009","unstructured":"Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, Worley PF, Kozma SC, Powell JD (2009) The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30: 832\u2013844","journal-title":"Immunity"},{"key":"BFEMBJ2022111614_CR16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ni.2005","volume":"124","author":"GM Delgoffe","year":"2011","unstructured":"Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, Xiao B, Worley PF, Powell JD (2011) The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 124: 295\u2013303","journal-title":"Nat Immunol"},{"key":"BFEMBJ2022111614_CR17","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.cell.2014.01.024","volume":"156","author":"C Demetriades","year":"2014","unstructured":"Demetriades C, Doumpas N, Teleman AA (2014) Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2. Cell 156: 786\u2013799","journal-title":"Cell"},{"key":"BFEMBJ2022111614_CR18","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1038\/s41388-019-0877-4","volume":"38","author":"L Deng","year":"2019","unstructured":"Deng L, Qian G, Zhang S, Zheng H, Fan S, Lesinski GB, Owonikoko TK, Ramalingam SS, Sun SY (2019) Inhibition of mTOR complex 1\/p70 S6 kinase signaling elevates PD\u2010L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced \u03b2\u2010TrCP degradation. Oncogene 38: 6270\u20136282","journal-title":"Oncogene"},{"key":"BFEMBJ2022111614_CR19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4049\/jimmunol.144.1.251","volume":"144","author":"FJ Dumont","year":"1990","unstructured":"Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH (1990) Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK\u2010506 and rapamycin. J Immunol 144: 251\u2013258","journal-title":"J Immunol"},{"key":"BFEMBJ2022111614_CR20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","volume":"39","author":"K D\u00fcvel","year":"2010","unstructured":"D\u00fcvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S et\u00a0al (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39: 171\u2013183","journal-title":"Mol Cell"},{"key":"BFEMBJ2022111614_CR21","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K (2019) CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 234: 8509\u20138521","journal-title":"J Cell Physiol"},{"key":"BFEMBJ2022111614_CR22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175\u2013191","journal-title":"Behav Res Methods"},{"key":"BFEMBJ2022111614_CR23","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.cub.2006.08.001","volume":"16","author":"MA Frias","year":"2006","unstructured":"Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, Sabatini DM (2006) mSin1 is necessary for Akt\/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16: 1865\u20131870","journal-title":"Curr Biol"},{"key":"BFEMBJ2022111614_CR24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE et\u00a0al (2016) Loss of IFN\u2010\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti\u2010CTLA\u20104 therapy. Cell 167: 397\u2013404","journal-title":"Cell"},{"key":"BFEMBJ2022111614_CR25","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1097-2765(03)00220-X","volume":"11","author":"A Garami","year":"2003","unstructured":"Garami A, Zwartkruis FJT, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G (2003) Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E\u2010BP signaling, is inhibited by TSC1 and 2. Mol Cell 11: 1457\u20131466","journal-title":"Mol Cell"},{"key":"BFEMBJ2022111614_CR26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A et\u00a0al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883\u2013892","journal-title":"N Engl J Med"},{"key":"BFEMBJ2022111614_CR27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M et\u00a0al (2019) Distinct immune cell populations define response to anti\u2010PD\u20101 monotherapy and anti\u2010PD\u20101\/anti\u2010CTLA\u20104 combined therapy. Cancer Cell 35: 238\u2013255","journal-title":"Cancer Cell"},{"key":"BFEMBJ2022111614_CR28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/hgtb.2014.004","volume":"25","author":"R Gomez\u2010Eerland","year":"2014","unstructured":"Gomez\u2010Eerland R, Nuijen B, Heemskerk B, van Rooij N, van den Berg JH, Beijnen JH, Uckert W, Kvistborg P, Schumacher TN, Haanen JBAG et\u00a0al (2014) Manufacture of gene\u2010modified human T\u2010cells with a memory stem\/central memory phenotype. Hum Gene Ther Methods 25: 277\u2013287","journal-title":"Hum Gene Ther Methods"},{"key":"BFEMBJ2022111614_CR29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/2159-8290.CD-13-0929","volume":"4","author":"BC Grabiner","year":"2014","unstructured":"Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH, Sabatini DM (2014) A diverse array of cancer\u2010associated mTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov 4: 554\u2013563","journal-title":"Cancer Discov"},{"key":"BFEMBJ2022111614_CR30","doi-asserted-by":"crossref","first-page":"22175","DOI":"10.1074\/jbc.M202014200","volume":"277","author":"A Grolleau","year":"2002","unstructured":"Grolleau A, Bowman J, Pradet\u2010Balade B, Puravs E, Hanash S, Garcia\u2010Sanz JA, Beretta L (2002) Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J Biol Chem 277: 22175\u201322184","journal-title":"J Biol Chem"},{"key":"BFEMBJ2022111614_CR31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1083\/jcb.200403069","volume":"166","author":"LS Harrington","year":"2004","unstructured":"Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR et\u00a0al (2004) The TSC1\u20102 tumor suppressor controls insulin\u2010PI3K signaling via regulation of IRS proteins. J Cell Biol 166: 213\u2013223","journal-title":"J Cell Biol"},{"key":"BFEMBJ2022111614_CR32","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.molcel.2018.04.024","volume":"70","author":"L He","year":"2018","unstructured":"He L, Gomes AP, Wang X, Yoon SO, Lee G, Nagiec MJ, Cho S, Chavez A, Islam T, Yu Y et\u00a0al (2018) mTORC1 promotes metabolic reprogramming by the suppression of GSK3\u2010dependent Foxk1 phosphorylation. Mol Cell 70: 949\u2013960","journal-title":"Mol Cell"},{"key":"BFEMBJ2022111614_CR33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et\u00a0al (2010) Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711\u2013723","journal-title":"N Engl J Med"},{"key":"BFEMBJ2022111614_CR34","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1091\/mbc.e08-12-1248","volume":"20","author":"N Hosokawa","year":"2009","unstructured":"Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, Iemura SI, Natsume T, Takehana K, Yamada N et\u00a0al (2009) Nutrient\u2010dependent mTORC1 association with the ULK1\u2010Atg13\u2010FIP200 complex required for autophagy. Mol Biol Cell 20: 1981\u20131991","journal-title":"Mol Biol Cell"},{"key":"BFEMBJ2022111614_CR35","first-page":"1","volume":"121","author":"H Hua","year":"2019","unstructured":"Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y (2019) Targeting mTOR for cancer therapy. J Hematol Oncol 121: 1\u201319","journal-title":"J Hematol Oncol"},{"key":"BFEMBJ2022111614_CR36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/BST0370217","volume":"37","author":"J Huang","year":"2009","unstructured":"Huang J, Manning BD (2009) A complex interplay between Akt, TSC2, and the two mTOR complexes. Biochem Soc Trans 37: 217\u2013222","journal-title":"Biochem Soc Trans"},{"key":"BFEMBJ2022111614_CR37","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1128\/MCB.00289-08","volume":"28","author":"J Huang","year":"2008","unstructured":"Huang J, Dibble CC, Matsuzaki M, Manning BD (2008) The TSC1\u2010TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 28: 4104\u20134115","journal-title":"Mol Cell Biol"},{"key":"BFEMBJ2022111614_CR38","volume":"8","author":"Q Huang","year":"2022","unstructured":"Huang Q, Li F, Hu H, Fang Z, Gao Z, Xia G, Ng WL, Khodadadi\u2010Jamayran A, Chen T, Deng J et\u00a0al (2022) Loss of TSC1\/TSC2 sensitizes immune checkpoint blockade in non\u2010small cell lung cancer. Sci Adv 8: eabi9533","journal-title":"Sci Adv"},{"key":"BFEMBJ2022111614_CR39","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","volume":"4","author":"K Inoki","year":"2002","unstructured":"Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648\u2013657","journal-title":"Nat Cell Biol"},{"key":"BFEMBJ2022111614_CR40","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","volume":"17","author":"K Inoki","year":"2003","unstructured":"Inoki K, Li Y, Xu T, Guan KL (2003a) Rheb GTpase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17: 1829\u20131834","journal-title":"Genes Dev"},{"key":"BFEMBJ2022111614_CR41","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","volume":"115","author":"K Inoki","year":"2003","unstructured":"Inoki K, Zhu T, Guan KL (2003b) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577\u2013590","journal-title":"Cell"},{"key":"BFEMBJ2022111614_CR42","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cell.2006.06.055","volume":"126","author":"K Inoki","year":"2006","unstructured":"Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K et\u00a0al (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955\u2013968","journal-title":"Cell"},{"key":"BFEMBJ2022111614_CR43","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ejca.2005.03.023","volume":"41","author":"WG Jiang","year":"2005","unstructured":"Jiang WG, Sampson J, Martin TA, Lee\u2010Jones L, Watkins G, Douglas\u2010Jones A, Mokbel K, Mansel RE (2005) Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the\u00a0role of promoter methylation of TSC genes. Eur J Cancer 41: 1628\u20131636","journal-title":"Eur J Cancer"},{"key":"BFEMBJ2022111614_CR44","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"2410","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B et\u00a0al (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 2410: 1550\u20131558","journal-title":"Nat Med"},{"key":"BFEMBJ2022111614_CR45","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.joca.2019.01.009","volume":"27","author":"Y Kakiuchi","year":"2019","unstructured":"Kakiuchi Y, Yurube T, Kakutani K, Takada T, Ito M, Takeoka Y, Kanda Y, Miyazaki S, Kuroda R, Nishida K (2019) Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction. Osteoarthr Cartil 27: 965\u2013976","journal-title":"Osteoarthr Cartil"},{"key":"BFEMBJ2022111614_CR46","first-page":"133","volume":"181","author":"YJ Kang","year":"2010","unstructured":"Kang YJ, Lu MK, Guan KL (2010) The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress\u2010induced apoptosis. Cell Death Differ 181: 133\u2013144","journal-title":"Cell Death Differ"},{"key":"BFEMBJ2022111614_CR47","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1101\/gad.11.6.701","volume":"11","author":"SG Kennedy","year":"1997","unstructured":"Kennedy SG, Wagner AJ, Conzen SD, Jord\u00e1n J, Bellacosa A, Tsichlis PN, Hay N (1997) The PI 3\u2010kinase\/Akt signaling pathway delivers an anti\u2010apoptotic signal. Genes Dev 11: 701\u2013713","journal-title":"Genes Dev"},{"key":"BFEMBJ2022111614_CR48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","volume":"110","author":"DH Kim","year":"2002","unstructured":"Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument\u2010Bromage H, Tempst P, Sabatini DM (2002) mTOR interacts with raptor to form a nutrient\u2010sensitive complex that signals to the cell growth machinery. Cell 110: 163\u2013175","journal-title":"Cell"},{"key":"BFEMBJ2022111614_CR49","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim J, Kundu M, Viollet B, Guan KL (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13: 132\u2013141","journal-title":"Nat Cell Biol"},{"key":"BFEMBJ2022111614_CR50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion\u2010Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et\u00a0al (2015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23\u201334","journal-title":"N Engl J Med"},{"key":"BFEMBJ2022111614_CR51","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion\u2010Sileni V, Gonzalez R, Grob J\u2010J, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R et\u00a0al (2019) Five\u2010year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 381: 1535\u20131546","journal-title":"N Engl J Med"},{"key":"BFEMBJ2022111614_CR52","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","volume":"76","author":"KJ Lastwika","year":"2016","unstructured":"Lastwika KJ, Wilson W, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S et\u00a0al (2016) Control of PD\u2010L1 expression by oncogenic activation of the AKT\u2010mTOR pathway in non\u2010small cell lung cancer. Cancer Res 76: 227\u2013238","journal-title":"Cancer Res"},{"key":"BFEMBJ2022111614_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41586-020-2746-2","volume":"586","author":"KA Lawson","year":"2020","unstructured":"Lawson KA, Sousa CM, Zhang X, Kim E, Akthar R, Caumanns JJ, Yao Y, Mikolajewicz N, Ross C, Brown KR et\u00a0al (2020) Functional genomic landscape of cancer\u2010intrinsic evasion of killing by T cells. Nature 586: 1\u20137","journal-title":"Nature"},{"key":"BFEMBJ2022111614_CR54","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, Irizarry RA, Liu JS, Brown M, Liu XS (2014) MAGeCK enables robust identification of essential genes from genome\u2010scale CRISPR\/Cas9 knockout screens. Genome Biol 15: 554","journal-title":"Genome Biol"},{"key":"BFEMBJ2022111614_CR55","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P (2015) The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst 1: 417\u2013425","journal-title":"Cell Syst"},{"key":"BFEMBJ2022111614_CR56","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, Watkins TBK, Rosenthal R, Biswas D, Rowan A et\u00a0al (2021) Meta\u2010analysis of tumor\u2010 and T cell\u2010intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184: 596\u2013614","journal-title":"Cell"},{"key":"BFEMBJ2022111614_CR57","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","volume":"214","author":"GY Liu","year":"2020","unstructured":"Liu GY, Sabatini DM (2020) mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol 214: 183\u2013203","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFEMBJ2022111614_CR58","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV et\u00a0al (2018) An integrated TCGA Pan\u2010cancer clinical data resource to drive high\u2010quality survival outcome analytics. Cell 173: 400\u2013416","journal-title":"Cell"},{"key":"BFEMBJ2022111614_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20110892","volume":"441","author":"B Magnuson","year":"2012","unstructured":"Magnuson B, Ekim B, Fingar DC (2012) Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 441: 1\u201321","journal-title":"Biochem J"},{"key":"BFEMBJ2022111614_CR60","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","volume":"10","author":"BD Manning","year":"2002","unstructured":"Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002) Identification of the tuberous sclerosis complex\u20102 tumor suppressor gene product tuberin as a target of the phosphoinositide 3\u2010kinase\/akt pathway. Mol Cell 10: 151\u2013162","journal-title":"Mol Cell"},{"key":"BFEMBJ2022111614_CR61","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","volume":"21","author":"L Mart\u00ednez\u2010Lostao","year":"2015","unstructured":"Mart\u00ednez\u2010Lostao L, Anel A, Pardo J (2015) How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res 21: 5047\u20135056","journal-title":"Clin Cancer Res"},{"key":"BFEMBJ2022111614_CR62","first-page":"S43","volume":"272","author":"S Menon","year":"2009","unstructured":"Menon S, Manning BD (2009) Common corruption of the mTOR signaling network in human tumors. Oncogene 272: S43\u2013S51","journal-title":"Oncogene"},{"key":"BFEMBJ2022111614_CR63","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cell.2013.11.049","volume":"156","author":"S Menon","year":"2014","unstructured":"Menon S, Dibble CC, Talbott G, Hoxhaj G, Valvezan AJ, Takahashi H, Cantley LC, Manning BD (2014) Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 156: 771\u2013785","journal-title":"Cell"},{"key":"BFEMBJ2022111614_CR64","first-page":"1","volume":"268","author":"O Meyuhas","year":"2008","unstructured":"Meyuhas O (2008) Physiological roles of ribosomal protein S6: one of its kind. Int Rev Cell Mol Biol 268: 1\u201337","journal-title":"Int Rev Cell Mol Biol"},{"key":"BFEMBJ2022111614_CR65","doi-asserted-by":"crossref","first-page":"545","DOI":"10.4161\/cc.8.4.7625","volume":"8","author":"RE Mills","year":"2009","unstructured":"Mills RE, Jameson JM (2009) T cell dependence on mTOR signaling. Cell Cycle 8: 545\u2013548","journal-title":"Cell Cycle"},{"key":"BFEMBJ2022111614_CR66","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1074\/jbc.M005196200","volume":"276","author":"A Nesterov","year":"2001","unstructured":"Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS (2001) Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL\u2010induced apoptosis. J Biol Chem 276: 10767\u201310774","journal-title":"J Biol Chem"},{"key":"BFEMBJ2022111614_CR67","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.4161\/auto.7.10.16681","volume":"7","author":"S Ng","year":"2011","unstructured":"Ng S, Wu YT, Chen B, Zhou J, Shen HM (2011) Impaired autophagy due to constitutive mTOR activation sensitizes TSC2\u2010null cells to cell death under stress. Autophagy 7: 1173\u20131186","journal-title":"Autophagy"},{"key":"BFEMBJ2022111614_CR68","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ncb840","volume":"4","author":"CJ Potter","year":"2002","unstructured":"Potter CJ, Pedraza LG, Xu T (2002) Akt regulates growth by directly phosphorylating TSC2. Nat Cell Biol 4: 658\u2013665","journal-title":"Nat Cell Biol"},{"key":"BFEMBJ2022111614_CR69","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.immuni.2009.10.010","volume":"32","author":"RR Rao","year":"2010","unstructured":"Rao RR, Li Q, Odunsi K, Shrikant PA (2010) The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T\u2010bet and Eomesodermin. Immunity 32: 67\u201378","journal-title":"Immunity"},{"key":"BFEMBJ2022111614_CR70","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Mart\u00edn\u2010Algarra S, Mandal R, Sharfman WH et\u00a0al (2017) Tumor and microenvironment evolution during immunotherapy with Nivolumab. Cell 171: 934\u2013949","journal-title":"Cell"},{"key":"BFEMBJ2022111614_CR71","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev.immunol.20.100201.131730","volume":"20","author":"JH Russell","year":"2002","unstructured":"Russell JH, Ley TJ (2002) Lymphocyte\u2010mediated cytotoxicity. Annu Rev Immunol 20: 323\u2013370","journal-title":"Annu Rev Immunol"},{"key":"BFEMBJ2022111614_CR72","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1038\/onc.2010.28","volume":"29","author":"T Sato","year":"2010","unstructured":"Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F (2010) Single amino\u2010acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 29: 2746\u20132752","journal-title":"Oncogene"},{"key":"BFEMBJ2022111614_CR73","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 168: 960\u2013976","journal-title":"Cell"},{"key":"BFEMBJ2022111614_CR74","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","volume":"35","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Wolchok JD, Stephen Hodi F, Chiarion\u2010Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Lance Cowey C, Lao CD, Chesney J et\u00a0al (2017) Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with Nivolumab and Ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 35: 3807\u20133814","journal-title":"J Clin Oncol"},{"key":"BFEMBJ2022111614_CR75","doi-asserted-by":"crossref","first-page":"D674","DOI":"10.1093\/nar\/gkn653","volume":"37","author":"CF Schaefer","year":"2009","unstructured":"Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH (2009) PID: the pathway interaction database. Nucleic Acids Res 37: D674\u2013D679","journal-title":"Nucleic Acids Res"},{"key":"BFEMBJ2022111614_CR76","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cub.2004.08.026","volume":"14","author":"OJ Shah","year":"2004","unstructured":"Shah OJ, Wang Z, Hunter T (2004) Inappropriate activation of the TSC\/Rheb\/mTOR\/S6K cassette induces IRS1\/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14: 1650\u20131656","journal-title":"Curr Biol"},{"key":"BFEMBJ2022111614_CR77","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu\u2010Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168: 707\u2013723","journal-title":"Cell"},{"key":"BFEMBJ2022111614_CR78","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-05-0068","volume":"4","author":"Y Shi","year":"2005","unstructured":"Shi Y, Yan H, Frost P, Gera J, Lichtenstein A (2005) Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up\u2010regulating the insulin\u2010like growth factor receptor\/insulin receptor substrate\u20101\/phosphatidylinositol 3\u2010kinase cascade. Mol Cancer Ther 4: 1533\u20131540","journal-title":"Mol Cancer Ther"},{"key":"BFEMBJ2022111614_CR79","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin\u2010Ordinas H, Garcia\u2010Diaz A, Hu\u2010Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY et\u00a0al (2017) Primary resistance to PD\u20101 blockade mediated by JAK1\/2 mutations. Cancer Discov 7: 188\u2013201","journal-title":"Cancer Discov"},{"key":"BFEMBJ2022111614_CR80","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/ni.1603","volume":"95","author":"LV Sinclair","year":"2008","unstructured":"Sinclair LV, Finlay D, Feijoo C, Cornish GH, Gray A, Ager A, Okkenhaug K, Hagenbeek TJ, Spits H, Cantrell DA (2008) Phosphatidylinositol\u20103\u2010OH kinase and nutrient\u2010sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 95: 513\u2013521","journal-title":"Nat Immunol"},{"key":"BFEMBJ2022111614_CR81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fmolb.2021.628332","volume":"8","author":"M Snajdauf","year":"2021","unstructured":"Snajdauf M, Havlova K, Vachtenheim J, Ozaniak A, Lischke R, Bartunkova J, Smrz D, Strizova Z (2021) The TRAIL in the treatment of human cancer: an update on clinical trials. Front Mol Biosci 8: 87","journal-title":"Front Mol Biosci"},{"key":"BFEMBJ2022111614_CR82","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF (2015) Melanoma\u2010intrinsic \u03b2\u2010catenin signalling prevents anti\u2010tumour immunity. Nature 523: 231\u2013235","journal-title":"Nature"},{"key":"BFEMBJ2022111614_CR83","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","volume":"65","author":"SY Sun","year":"2005","unstructured":"Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR (2005) Activation of Akt and eIF4E survival pathways by rapamycin\u2010mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052\u20137058","journal-title":"Cancer Res"},{"key":"BFEMBJ2022111614_CR84","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","volume":"13","author":"AR Tee","year":"2003","unstructured":"Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J (2003) Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase\u2010activating protein complex toward Rheb. Curr Biol 13: 1259\u20131268","journal-title":"Curr Biol"},{"key":"BFEMBJ2022111614_CR85","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN (2018) T cell dysfunction in cancer. Cancer Cell 33: 547\u2013562","journal-title":"Cancer Cell"},{"key":"BFEMBJ2022111614_CR86","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ccell.2017.09.013","volume":"32","author":"AJ Valvezan","year":"2017","unstructured":"Valvezan AJ, Turner M, Belaid A, Lam HC, Miller SK, McNamara MC, Baglini C, Housden BE, Perrimon N, Kwiatkowski DJ et\u00a0al (2017) mTORC1 couples nucleotide synthesis to nucleotide demand resulting in a targetable metabolic vulnerability. Cancer Cell 32: 624\u2013638","journal-title":"Cancer Cell"},{"key":"BFEMBJ2022111614_CR87","doi-asserted-by":"publisher","first-page":"100043","DOI":"10.1016\/j.iotech.2021.100043","volume":"11","author":"DW Vredevoogd","year":"2021","unstructured":"Vredevoogd DW, Apriamashvili G, Peeper DS (2021) The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens. Immunooncol Technol 11: 100043. https:\/\/doi.org\/10.1016\/j.iotech.2021.100043","journal-title":"Immunooncol Technol"},{"key":"BFEMBJ2022111614_CR88","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cell.2019.06.014","volume":"178","author":"DW Vredevoogd","year":"2019","unstructured":"Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, Krijgsman O, Huang X, Kenski JCN, Lacroix R et\u00a0al (2019) Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold. Cell 178: 585\u2013599","journal-title":"Cell"},{"key":"BFEMBJ2022111614_CR89","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1038\/sj.onc.1207232","volume":"22","author":"S Wang","year":"2003","unstructured":"Wang S, El\u2010Deiry WS (2003) TRAIL and apoptosis induction by TNF\u2010family death receptors. Oncogene 22: 8628\u20138633","journal-title":"Oncogene"},{"key":"BFEMBJ2022111614_CR90","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.4161\/auto.26447","volume":"9","author":"Y Wang","year":"2013","unstructured":"Wang Y, Hu Z, Liu Z, Chen R, Peng H, Guo J, Chen X, Zhang H (2013) MTOR inhibition attenuates DNA damage and apoptosis through autophagy\u2010mediated suppression of CREB1. Autophagy 9: 2069\u20132086","journal-title":"Autophagy"},{"key":"BFEMBJ2022111614_CR91","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","volume":"158","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 158: 486\u2013499","journal-title":"Nat Rev Immunol"},{"key":"BFEMBJ2022111614_CR92","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion\u2010Sileni V, Gonzalez R, Rutkowski P, Grob J\u2010J, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF et\u00a0al (2017) Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 377: 1345\u20131356","journal-title":"N Engl J Med"},{"key":"BFEMBJ2022111614_CR93","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.leukres.2009.01.041","volume":"33","author":"Z Xu","year":"2009","unstructured":"Xu Z, Wang M, Wang L, Wang Y, Zhao X, Rao Q, Wang J (2009) Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. Leuk Res 33: 891\u2013897","journal-title":"Leuk Res"},{"key":"BFEMBJ2022111614_CR94","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nprot.2010.43","volume":"5","author":"L Young","year":"2010","unstructured":"Young L, Sung J, Masters JR (2010) Detection of mycoplasma in cell cultures. Nat Protoc 5: 929\u2013934","journal-title":"Nat Protoc"},{"key":"BFEMBJ2022111614_CR95","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia\u2010Diaz A, Shin DS, Escuin\u2010Ordinas H, Hugo W, Hu\u2010Lieskovan S, Torrejon DY, Abril\u2010Rodriguez G, Sandoval S, Barthly L et\u00a0al (2016) Mutations associated with acquired resistance to PD\u20101 blockade in melanoma. N Engl J Med 375: 819\u2013829","journal-title":"N Engl J Med"},{"key":"BFEMBJ2022111614_CR96","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","volume":"22","author":"HM Zarour","year":"2016","unstructured":"Zarour HM (2016) Reversing T\u2010cell dysfunction and exhaustion in cancer. Clin Cancer Res 22: 1856\u20131864","journal-title":"Clin Cancer Res"},{"key":"BFEMBJ2022111614_CR97","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ncb999","volume":"5","author":"Y Zhang","year":"2003","unstructured":"Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5: 578\u2013581","journal-title":"Nat Cell Biol"},{"key":"BFEMBJ2022111614_CR98","doi-asserted-by":"publisher","first-page":"100655","DOI":"10.1016\/j.xcrm.2022.100655","volume":"3","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Kong X, Ligtenberg MA, van Hal-van Veen SE, Visser NL, de Bruijn B, Stecker K, van der Helm PW, Kuilman T, Hoefsmit EP et\u00a0al (2022) RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells. Cell Rep Med 3: 100655. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100655","journal-title":"Cell Rep Med"},{"key":"BFEMBJ2022111614_CR99","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.4049\/jimmunol.178.4.2163","volume":"178","author":"Y Zheng","year":"2007","unstructured":"Zheng Y, Collins SL, Lutz MA, Allen AN, Kole TP, Zarek PE, Powell JD (2007) A role for mammalian target of rapamycin in regulating T cell activation versus Anergy. J Immunol 178: 2163\u20132170","journal-title":"J Immunol"},{"key":"BFEMBJ2022111614_CR100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-13-78","volume":"13","author":"RM Zimmerer","year":"2013","unstructured":"Zimmerer RM, Korn P, Demougin P, Kampmann A, Kokem\u00fcller H, Eckardt AM, Gellrich NC, Tavassol F (2013) Functional features of cancer stem cells in melanoma cell lines. Cancer Cell Int 13: 1\u201313","journal-title":"Cancer Cell Int"}],"container-title":["The EMBO Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/embj.2022111614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.15252\/embj.2022111614","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.15252\/embj.2022111614\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.15252\/embj.2022111614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/embj.2022111614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:34:54Z","timestamp":1779309294000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.15252\/embj.2022111614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,3,1]]}},"alternative-id":["BFEMBJ2022111614"],"URL":"https:\/\/doi.org\/10.15252\/embj.2022111614","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.05.09.491124","asserted-by":"object"}]},"ISSN":["0261-4189","1460-2075"],"issn-type":[{"value":"0261-4189","type":"print"},{"value":"1460-2075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"8 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"EMBJ2022111614"}}